AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31161722 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study 27248848 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Ultrasonic Irrigation (CUI)
Number of subjects: 70
Study 27248848 — intervention group
Group type: COMPARATOR
Intervention: Syringe Irrigation (SI)
Number of subjects: 70
Study 25994442 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine F2‐isoprostanes at the end of surgery
Number of subjects: 551
Study 25994442 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine isofurans at the end of surgery
Number of subjects: 551
Study 25994442 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine F3‐isoprostanes at the end of surgery
Number of subjects: 551
Study 23625485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid valve detachment (TVD) for VSD closure
Number of subjects: 35
Study 23625485 — intervention group
Group type: COMPARATOR
Intervention: Closure without tricuspid valve detachment (control)
Number of subjects: 35
Study 21304923 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTc with sulphadoxine pyrimethamine (SP) plus amodiaquine (AQ)
Number of subjects: 3017
Study 19211603 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1%
Number of subjects: 400
Study 19211603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 16769273 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 60
Study 16769273 — intervention group
Group type: COMPARATOR
Intervention: Conventional clamping methods
Number of subjects: 60
Study 14742400 — intervention group
Group type: EXPERIMENTAL
Intervention: Music played during surgery
Number of subjects: 30
Study 14742400 — intervention group
Group type: COMPARATOR
Intervention: No music played (control group)
Number of subjects: 30
Study 11282447 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic drinks (0.7 g/kg)
Number of subjects: 19
Study 11282447 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free drinks
Number of subjects: 19
Study 9215018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal lignocaine (50 ml containing 200 mg lignocaine and 1:500,000 adrenaline)
Number of subjects: 39
Study 9215018 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 ml saline i.p.)
Number of subjects: 39
Study 8116338 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific cognitive treatment (20 pts) including direct training, compensatory strategies, and neuropsychotherapy
Number of subjects: 40
Study 8116338 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific cognitive treatment (20 pts)
Number of subjects: 40
Study 8116338 — intervention group
Group type: COMPARATOR
Intervention: Non-specific, deliberately diffuse mental stimulation (20 pts)
Number of subjects: 40
Study 3547053 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of elemental zinc (as 220 mg zinc sulphate), three times a day for six weeks
Number of subjects: 47
Study 3547053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 3547053 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of zinc a day
Number of subjects: 47
Study 30029621 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling (Group A)
Number of subjects: 60
Study 30029621 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted ILM flap (Group B)
Number of subjects: 60
Study 28401310 — intervention group
Group type: EXPERIMENTAL
Intervention: Block periodised resistance training
Number of subjects: 41
Study 28401310 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily undulating periodised resistance training
Number of subjects: 41
Study 28401310 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-periodised resistance training
Number of subjects: 41
Study 28401310 — intervention group
Group type: COMPARATOR
Intervention: All training groups (BP, DUP, NP)
Number of subjects: 41
Study 26553211 — intervention group
Group type: COMPARATOR
Intervention: Unblinded tracking
Number of subjects: 48
Study 26553211 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart texts
Number of subjects: 48
Study 23751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair (EVAR); surgical success rate 100%, perioperative mortality rate 0.8%, mean operative duration 150 min, mean blood loss 140 ml, mean hospitalization time 15.5 days, mean hospitalization cost RMB 104,800; stent graft patency 96% (120 cases), 10 deaths, 8 complications (5.6%).
Number of subjects: 218
Study 23751738 — intervention group
Group type: COMPARATOR
Intervention: Open surgery; surgical success rate 98.8%, perioperative mortality rate 2.3%, mean operative duration 230 min, mean blood loss 450 ml, mean hospitalization time 30 ± 3 days, mean hospitalization cost RMB 58,000; stent graft patency 98.8% (79 cases), 8 deaths (10%).
Number of subjects: 218
Study 23751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of long-term effects between EVAR and open surgery;
Number of subjects: 218
Study 20734238 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume enriched diet (1.5 servings/1,000 kcal), high fiber (21 g/1,000 kcal), low GI (GI = 38)
Number of subjects: 64
Study 20734238 — intervention group
Group type: COMPARATOR
Intervention: Healthy American diet (no legume consumption, fiber consumption = 9 g/1,000 kcal, GI = 69)
Number of subjects: 64
Study 18565239 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg and 10 mg)
Number of subjects: 0
Study 18565239 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine (IR 2 mg bd/ER 4 mg)
Number of subjects: 0
Study 15972086 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (540 mg/day during maintenance phase)
Number of subjects: 25
Study 15972086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12709185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist facilitated teaching session
Number of subjects: 40
Study 12709185 — intervention group
Group type: COMPARATOR
Intervention: No additional teaching (Control)
Number of subjects: 40
Study 10505585 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg for 3 to 5 days
Number of subjects: 106
Study 10505585 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 to 5 days
Number of subjects: 106
Study 10505585 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label olanzapine (10-25 mg/day) for 9 weeks
Number of subjects: 106
Study 7545986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-exposure intervention
Number of subjects: 0
Study 7545986 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cue-exposure sessions)
Number of subjects: 0
Study 1669122 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 48
Study 1669122 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 48
Study 1669122 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 48
Study 7006561 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by cyclophosphamide (100 mg/kg BW in daily intravenous doses of 200 mg)
Number of subjects: 372
Study 7006561 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (about 5500 rad tumour dose by telecobalt) and surgery
Number of subjects: 372
Study 7006561 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 372
Study 31819948 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone
Number of subjects: 62
Study 31819948 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with chemotherapy and/or thermotherapy
Number of subjects: 62
Study 31819948 — intervention group
Group type: EXPERIMENTAL
Intervention: High HPV viral load
Number of subjects: 62
Study 31399033 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 31399033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27352956 — intervention group
Group type: EXPERIMENTAL
Intervention: High onion group (HO; n = 28) - 100 to 160 g/d of onion for 8 weeks
Number of subjects: 56
Study 27352956 — intervention group
Group type: COMPARATOR
Intervention: Low onion group (LO; n = 28) - 30 to 40 g/d small onions for 8 weeks
Number of subjects: 56
Study 27352956 — intervention group
Group type: EXPERIMENTAL
Intervention: High onion group (HO; n = 28)
Number of subjects: 56
Study 25652804 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus usual care
Number of subjects: 0
Study 25652804 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study 24054337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141
Study 24054337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7141
Study 20960436 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 25
Study 20960436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19642002 — intervention group
Group type: COMPARATOR
Intervention: Non-white immigrants
Number of subjects: 5464
Study 19642002 — intervention group
Group type: COMPARATOR
Intervention: White male immigrants
Number of subjects: 5464
Study 19642002 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian born individuals
Number of subjects: 5464
Study 19642002 — intervention group
Group type: EXPERIMENTAL
Intervention: White immigrants
Number of subjects: 5464
Study 17431101 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational agent (growth-inhibitory drug) during the run-in period, followed by randomization to continue or discontinue therapy.
Number of subjects: 0
Study 17431101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) during the double-blind phase after the run-in period.
Number of subjects: 0
Study 15173844 — intervention group
Group type: COMPARATOR
Intervention: 0 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Number of subjects: 22
Study 15173844 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Number of subjects: 22
Study 15173844 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Number of subjects: 22
Study 11224687 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine
Number of subjects: 0
Study 11224687 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study 11224687 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrates
Number of subjects: 0
Study 11224687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Butyrates + Hydroxyurea)
Number of subjects: 0
Study 9138198 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavior modification intervention consisting of 5 weekly, 90-min sessions including skill training, self-monitoring, weekly feedback, and group support
Number of subjects: 107
Study 9138198 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavior modification intervention
Number of subjects: 107
Study 9138198 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 107
Study 7949260 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation of biscuits containing raw fibre and lactulose (Fiberlac, Bracco)
Number of subjects: 10
Study 2975091 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (1 mg intracoronarily)
Number of subjects: 20
Study 2975091 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intracoronarily)
Number of subjects: 20
Study 29430970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Exposure Physical Therapy (maximum of five sessions)
Number of subjects: 56
Study 29430970 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment conforming with the Dutch multidisciplinary guideline
Number of subjects: 56
Study 28529951 — intervention group
Group type: EXPERIMENTAL
Intervention: UCMCs transfusion
Number of subjects: 63
Study 28529951 — intervention group
Group type: COMPARATOR
Intervention: Control group (without transplantation)
Number of subjects: 63
Study 26232133 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan with conventional or intensive diet education
Number of subjects: 229
Study 23941670 — intervention group
Group type: COMPARATOR
Intervention: 2.5 g/kg/day of amino acids (standard AA [SAA] group)
Number of subjects: 131
Study 23941670 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/kg/day of amino acids (high AA [HAA] group)
Number of subjects: 131
Study 23941670 — intervention group
Group type: COMPARATOR
Intervention: 2.5 g/kg/day of amino acids (SAA group)
Number of subjects: 131
Study 23941670 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/kg/day of amino acids (HAA group)
Number of subjects: 131
Study 23941670 — intervention group
Group type: COMPARATOR
Intervention: Body weight, length, and head circumference at 36 weeks
Number of subjects: 131
Study 23941670 — intervention group
Group type: COMPARATOR
Intervention: Bayley Scales of Infant and Toddler Development, Third Edition score in SAA group
Number of subjects: 131
Study 23941670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant and Toddler Development, Third Edition score in HAA group
Number of subjects: 131
Study 21923847 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (long-acting analogue; LAA)
Number of subjects: 120
Study 21923847 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% insulin aspart protamine and 30% insulin aspart (biphasic insulin analogue; BIA)
Number of subjects: 120
Study 21923847 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily BIA therapy
Number of subjects: 120
Study 19808287 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment and device-guided paced breathing (n=12)
Number of subjects: 24
Study 19808287 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n=12)
Number of subjects: 24
Study 16478629 — intervention group
Group type: EXPERIMENTAL
Intervention: CIAIV‐CCRT (intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil)
Number of subjects: 45
Study 16478629 — intervention group
Group type: COMPARATOR
Intervention: Control group (radiation therapy alone)
Number of subjects: 45
Study 12882847 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg daily
Number of subjects: 20
Study 12882847 — intervention group
Group type: COMPARATOR
Intervention: ACEI alone (lisinopril/enalapril 40 mg daily or captopril 150 mg daily)
Number of subjects: 20
Study 11056590 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 Immunogen
Number of subjects: 2527
Study 11056590 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2527
Study 8791245 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-Diaminopyridine (DAP)
Number of subjects: 9
Study 8791245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1463179 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia plus thoracic epidural blockade with 0.5% bupivacaine
Number of subjects: 20
Study 1463179 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 20
Study 6388424 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxsuprine
Number of subjects: 60
Study 6388424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31196142 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28805468 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pill fixed-dose combination therapy
Number of subjects: 12433
Study 28805468 — intervention group
Group type: COMPARATOR
Intervention: Two-pills combination therapy
Number of subjects: 12433
Study 26373701 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 21
Study 26373701 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate diet
Number of subjects: 21
Study 26373701 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 21
Study 23851000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) (N=30)
Number of subjects: 67
Study 23851000 — intervention group
Group type: COMPARATOR
Intervention: Child-Centered Therapy (CCT) (N=17)
Number of subjects: 67
Study 23851000 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment encouragement of bravery
Number of subjects: 67
Study 21877998 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg q.d. for 4 months
Number of subjects: 12
Study 21877998 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 12
Study 19722442 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid (Group 1)
Number of subjects: 60
Study 19722442 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid and a single-bottle dentin bonding agent (Group 2)
Number of subjects: 60
Study 19722442 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive (Group 3)
Number of subjects: 60
Study 18086056 — intervention group
Group type: EXPERIMENTAL
Intervention: NASHA (Restylane and/or Perlane, mean dosage 69 mg)
Number of subjects: 433
Study 15263832 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalin 0.1 mg with 10 ml 0.9% NaCl (1/100,000 dilution)
Number of subjects: 51
Study 15263832 — intervention group
Group type: COMPARATOR
Intervention: Physiological serum solution
Number of subjects: 51
Study 11427321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular infusion of 0.5 ml hypertonic saline (6%) into the tibialis anterior muscle
Number of subjects: 14
Study 9708870 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7820712 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid instillation of Exosurf (5 minutes)
Number of subjects: 27
Study 7820712 — intervention group
Group type: COMPARATOR
Intervention: Slow instillation of Exosurf (15 minutes)
Number of subjects: 27
Study 7820712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Rapid and Slow)
Number of subjects: 27
Study 3344411 — intervention group
Group type: EXPERIMENTAL
Intervention: APD 30 mg
Number of subjects: 40
Study 3344411 — intervention group
Group type: EXPERIMENTAL
Intervention: APD 45 mg
Number of subjects: 40
Study 3344411 — intervention group
Group type: EXPERIMENTAL
Intervention: APD 60 mg
Number of subjects: 40
Study 3344411 — intervention group
Group type: EXPERIMENTAL
Intervention: APD 90 mg
Number of subjects: 40
Study 3344411 — intervention group
Group type: EXPERIMENTAL
Intervention: APD (all doses)
Number of subjects: 40
Study 29957150 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (telepresent senior physician team leader)
Number of subjects: 20
Study 29957150 — intervention group
Group type: COMPARATOR
Intervention: Usual care (both physicians in the room)
Number of subjects: 20
Study 28166253 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high saturated fat diet (HSF; 39%E carbohydrate, 25%E protein, 36%E fat, 18%E saturated fat)
Number of subjects: 53
Study 28166253 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high saturated fat diet (HSF)
Number of subjects: 53
Study 25478757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 50
Study 25478757 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy guidance
Number of subjects: 50
Study 23497760 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg alone
Number of subjects: 59
Study 23497760 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin 25 mg with verapamil 120 mg
Number of subjects: 59
Study 23497760 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg QD for 5 days with ramipril (2.5 mg on day 1 then 5 mg QD on days 2‐5)
Number of subjects: 59
Study 23497760 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (2.5 mg on day 1 then 5 mg QD on days 2‐5)
Number of subjects: 59
Study 23497760 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg QD for 8 days with single‐dose digoxin 0.5 mg on day 5
Number of subjects: 59
Study 23497760 — intervention group
Group type: COMPARATOR
Intervention: Single‐dose digoxin 0.5 mg alone
Number of subjects: 59
Study 22050797 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atenolol 50 mg twice daily for one day prior to surgery (Group I)
Number of subjects: 105
Study 22050797 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative nitroprusside infusion (Group II)
Number of subjects: 105
Study 22050797 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative esmolol infusion (Group III)
Number of subjects: 105
Study 22050797 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and esmolol groups
Number of subjects: 105
Study 22050797 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 105
Study 18435833 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg
Number of subjects: 9075
Study 18435833 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav 375 mg
Number of subjects: 9075
Study 18435833 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics (general)
Number of subjects: 9075
Study 18435833 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental questionnaire
Number of subjects: 9075
Study 18435833 — intervention group
Group type: EXPERIMENTAL
Intervention: National standard test results
Number of subjects: 9075
Study 17310784 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox) 400 mg every 24 hours, first intravenously then orally, for a total treatment duration of 7 to 12 days (average 8.45 ± 1.53 days).
Number of subjects: 22
Study 17310784 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin treatment.
Number of subjects: 22
Study 12932070 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (standard doses for at least 4 months)
Number of subjects: 15
Study 12932070 — intervention group
Group type: COMPARATOR
Intervention: Control (no atorvastatin)
Number of subjects: 15
Study 10698243 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone messages followed by letters (Group A)
Number of subjects: 1227
Study 10698243 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone messages alone (Group B)
Number of subjects: 1227
Study 10698243 — intervention group
Group type: EXPERIMENTAL
Intervention: Letters only (Group C)
Number of subjects: 1227
Study 10698243 — intervention group
Group type: COMPARATOR
Intervention: No notification (Group D)
Number of subjects: 1227